REPLIMUNE GROUP, INC. Adjustments to Additional Paid in Capital, Warrant Issued
REPLIMUNE GROUP, INC. (REPL) reported Adjustments to Additional Paid in Capital, Warrant Issued of $91.65 million for the 12-month period ending 2021-03-31, per its 10-K filed 2022-05-19.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2022-05-19
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2020-12-31 was $58.75M, a 108.74% increase year-over-year.
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2020-06-30 was $32.90M.
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2019-12-31 was $28.14M, a 64.49% decline year-over-year.
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2019-03-31 was -$79.27M.
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, warrant issued for fiscal 2021 was $91.65M, a 225.64% increase from fiscal 2020.
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, warrant issued for fiscal 2020 was $28.14M, a 296.74% increase from fiscal 2019.
- REPLIMUNE GROUP, INC. adjustments to additional paid in capital, warrant issued for fiscal 2019 was $7.09M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month as first filed | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $91.65M 10-K · filed 2022-05-19 | ||||
| 2020-12-31 | $58.75M 10-Q · filed 2022-02-03 | ||||
| 2020-06-30 | $32.90M 10-Q · filed 2022-02-03 | ||||
| 2020-03-31 | $28.14M 10-K · filed 2021-05-20 | ||||
| 2019-12-31 | $28.14M 10-Q · filed 2021-02-04 | ||||
| 2019-03-31 | -$79.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $0.00 derived: sum of 2 quarters · filed 2020-06-03 | $7.09M derived: sum of 3 quarters · filed 2020-06-03 | $7.09M 10-K · filed 2020-06-03 | |
| 2018-12-31 | $79.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-13 | $86.36M derived: sum of 2 quarters · filed 2020-02-13 | $86.36M 10-Q · filed 2020-02-13 | $7.09M 10-Q · filed 2019-02-14 | |
| 2018-09-30 | $7.09M 10-Q · filed 2020-02-13 | $7.09M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |